AbbVie 8-K
PositiveDeal pending
Deal to acquire Apogee would add zumilokibart for atopic dermatitis and APG273 for asthma to the immunology pipeline.
Filed 2026-06-22 07:11 ET
- 7.01 Regulation FD Disclosure
- 9.01 Financial Statements and Exhibits
Summary
AbbVie agreed to acquire Apogee Therapeutics in an all-cash deal, adding clinical-stage programs for atopic dermatitis, asthma and other inflammatory diseases to its immunology pipeline. The acquisition is expected to close in Q3 2026, subject to Apogee shareholder and regulatory approvals.
Key Figures
- Purchase price: $135.11 per Apogee share in cash; approximately $10.9B total equity value, a ≈49% premium to Apogee’s 6/18/2026 closing price.
- Implied transaction value: ≈$10.1B net of estimated cash and marketable securities acquired; this calculation includes the impact of a buy-back option tied to Apogee’s revenue-sharing agreement with Blackstone Life Sciences.
- Financing: AbbVie expects to fund the transaction with debt. It expects to maintain its A2/A- credit rating and targets a 2x net leverage ratio within 2–3 years after closing.
- Pipeline: Apogee’s lead asset, zumilokibart, is a late-stage anti-IL-13 antibody in development for atopic dermatitis; APG273, an IL-13/TSLP combination, is in development for asthma.
Guidance
| Metric | Period | Guidance | Prior | Direction |
|---|---|---|---|---|
| Adjusted diluted EPS impact | 2026, partial year | $(0.14) | — | — |
| Adjusted diluted EPS impact | 2027 | $(0.46) | — | — |
| Adjusted diluted EPS accretion | Beginning in 2032 | Accretive; amount not stated | — | — |
Investor Takeaways
- Apogee shareholder approval and regulatory approvals will determine whether the deal closes on the expected Q3 2026 schedule.
- Clinical progress to watch includes the planned start of zumilokibart Phase 3 atopic dermatitis trials in 2H 2026 and the expected announcement of APG273 trial plans in 2H 2026.
The summary is written by an AI model reading the filing.
Model 005 · prompt 01d34d48e3